Feb 22, 2008 - Artisan Pharma, Inc. today announced that the Japanese Pharmaceutical and Medical Device Agency approved Artisan's lead drug, ART-123 (human, soluble, recombinant thrombomodulin), on January 25, 2008 for the treatment of disseminated intravascular coagulation ("DIC") in Japan.
The approval of ART-123, which was received by Artisan's partner and licensor of ART-123, Asahi Kasei Pharma Corporation ("AKP"), further establishes AKP as a leader in biologic pharmaceutical product development.
About ART-123
ART-123 is a novel, recombinant, soluble thrombomodulin for the treatment of DIC (disseminated intravascular coagulation) in sepsis. ART-123 uniquely targets both anti-coagulant and systemic anti-inflammatory pathways, and holds great promise as a self-regulating treatment of DIC in sepsis. Artisan licensed ART-123 from Asahi Kasei Pharma Corporation and holds all development and commercial rights for ART-123 outside of Japan, China, Taiwan and Korea.
No comments:
Post a Comment